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With the beneficial goal of generating new applications 
from known drugs, the chemistry and biology groups 
of Asst Prof Martin J. Lear and Assoc Prof Yao Shao Qin 
have teamed up to develop an anti-cancer agent out 
of the FDA-approved anti-obesity drug called Orlistat 
(also known as tetrahydrolipstatin, THL). The findings 
of their research have been published in the prestigious 
Journal of the American Chemical Society and will be 
featured in the November 2010 issue of Chemical 
Communications[1,2].
Their strategy combines the techniques of total synthesis 
and chemical proteomics to generate THL-probes 
capable of trapping off-target proteins (Figure 1). 
These probes were synthesized through the introduction 
of alkyne handles in the parental THL structure to 
maintain the native biological properties of Orlistat, 
while still providing the necessary functionality for target 
identification via bio-orthogonal click chemistry. With 
these probes, they were able to demonstrate for the first 
time that this chemical proteomic approach is suitable 
for the identification of previously unknown cellular 
targets, i.e., the off -targets of Orlistat. 
Through their approach, several anticancer related 
proteins including HSP90 and three ribosomal proteins 
have been identified[1], as well as more specific THL-
analogues against a validated anti-cancer target called 
fatty acid synthase (FAS)[2]. Some of these new targets 
were further validated by experiments including Western 
blotting, recombinant protein expression and site-
directed mutagenesis. 
The chemical key to the success of their approach resides 
in the use of bio-compatible/bio-orthogonal “click” 
chemistry (between azides and alkynes) to not only 
rapidly diversify a compound library, but also to allow 
the activity-based protein profiling (ABPP) of cellular off-
targets of lead compounds (Figure 2).
The findings of this research have important implications 
in the consideration of Orlistat as a potential anti-cancer 
drug at its early stage of development for cancer therapy. 
This strategy should be broadly useful for off-target 
identification against a number of existing drugs and/or 
candidates, which are known to covalently modify their 
biological targets. With this breakthrough, the future can 
now promise to reveal new directions for old drugs. 
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Fig. 2 Activity-based protein profiling
Fig. 1 Trapping off-target proteins
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